GLP-1 Treatment During Menopause

GLP-1 is a hormone involved in appetite and blood glucose regulation. Medicines that activate its receptor can reduce hunger and food intake. They also affect insulin release and slow stomach emptying. That combination helps explain both the intended benefit and some digestive side effects.

Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors, so it is a dual incretin medicine, although it is often discussed alongside GLP-1 treatment. The medicines have different formulations, instructions, and indications.

A lower appetite may mean becoming satisfied with a smaller meal or having less desire to snack. The experience varies. The aim is an appropriate improvement in weight-related health with adequate nutrition and tolerable treatment.

Menopause can change body composition and fat distribution. SWAN studies found increases in central fat and a decline in lean soft tissue around the transition. A larger waist may accompany glucose or blood pressure concerns even when scale weight changes gradually.

A clinician should review the whole weight history: activity, sleep, eating patterns, medication, previous losses, and weight-related conditions. Hot flashes or insomnia can make daily routines harder. Those symptoms can receive menopause treatment while weight care addresses its own goals.

For adult weight management, the usual starting criteria are a BMI of at least 30, or at least 27 with a weight-related condition. Meeting that threshold still requires a review of suitability. A medicine prescribed for diabetes, cardiovascular risk, or sleep apnea may have additional criteria.

Milligram doses cannot be compared directly across these medicines or formulations. Use the prescribed product and written instructions. The Wegovy and Zepbound labels advise against combining them with another GLP-1 medicine; a switch needs its own clinical plan.

Large weight trials included many women, but their main results were collected in broader adult populations. They do not establish that menopause requires a special dose or predicts an individual response. Diabetes, starting weight, treatment tolerance, and adherence can influence results.

A 2024 retrospective study followed 106 postmenopausal women receiving semaglutide. Sixteen used hormone therapy and 90 did not. The hormone-therapy group had greater average weight loss, including 16% compared with 12% at 12 months. Both groups improved some cardiometabolic measures.

Participants were not randomly assigned to hormone therapy, and the groups differed in some health characteristics. The study therefore cannot establish that adding hormones causes greater weight loss. It is a reason for further research, with hormone therapy chosen according to its established clinical indications.

Smaller meals still need enough protein, energy, fiber, vitamins, and minerals. A dietitian can help if you become full quickly, struggle with nausea, or repeatedly skip meals. Kidney disease or another dietary restriction may change the appropriate protein and fluid advice.

Use physical function as part of follow-up. Strength work on at least two days each week is recommended for adults, alongside aerobic activity. Adapt the routine to your ability and review weakness, poor recovery, or persistent difficulty eating with the care team.

Nausea, constipation, diarrhea, vomiting, reflux, and abdominal discomfort are common adverse effects. Explain their timing, severity, and effect on eating or drinking before the next dose increase. Severe or persistent symptoms may require a dose review or investigation.

• A personal or family history of medullary thyroid cancer or MEN 2, and any previous severe allergic reaction to the medicine.
• Pancreatitis, gallbladder disease, severe gastroparesis, kidney problems, or diabetic eye disease.
• Insulin or sulfonylurea use, with a plan to reduce the risk of low blood glucose.
• Pregnancy plans, contraception, all oral medicines, and any upcoming anesthesia or procedure.

During perimenopause, ovulation can still occur. Wegovy's weight-treatment instructions require stopping at least two months before a planned pregnancy. Zepbound can reduce oral hormonal contraceptive effectiveness; its label calls for a nonoral method or an added barrier method for four weeks after starting and each dose increase.

Agree on follow-up and a plan for long-term access. Weight regain can occur when treatment stops. Confirm the pharmacy and formulation, particularly if a compounded product is proposed, because compounded medicines do not undergo FDA approval review.